Aradigm to Participate in FDA Workshop on Non-Cystic Fibrosis Bronchiectasis

Aradigm to Participate in FDA Workshop on Non-Cystic Fibrosis Bronchiectasis

Aradigm CorporationNancy Pecota, 510-265-8800Chief Financial Officer

Aradigm Corporation (OTCBB:ARDM) (the “Company”) today announced that Igor Gonda, PhD., Aradigm’s President and CEO, will be a panel member at the U.S. Food and Drug Administration’s public workshop regarding the design of clinical trials of antibacterial drugs for the treatment of non-cystic fibrosis bronchiectasis at the Sheraton Silver Spring Hotel in Silver Spring, MD on Friday, September 7, 2012 from 8:00 am to 3:30 pm Eastern time.

The public workshop is intended to provide information for and gain perspective from health care providers, patients and patient advocacy organizations, academia, and industry on various aspects of the design of clinical trials.

A draft agenda for the workshop may be obtained on the FDA website at .

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases by pulmonologists. The Company has product candidates addressing the treatment of bronchiectasis, cystic fibrosis, inhalation tularemia and anthrax infections, and prevention of respiratory and other diseases in tobacco smokers through smoking cessation.

More information about Aradigm can be found at .

Aradigm and the Aradigm Logo are registered trademarks of Aradigm Corporation.

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.